Welcome to LookChem.com Sign In|Join Free
  • or
Ticagrelor, an antiplatelet drug, is a medication that inhibits platelet activation and aggregation, thereby reducing the risk of blood clot formation. It specifically targets the P2Y12 receptor on platelets, preventing their activation and subsequent clumping. Ticagrelor is often used in combination with aspirin to further decrease the risk of cardiovascular events in patients with acute coronary syndrome or a history of heart attack.

1129683-88-0

Post Buying Request

1129683-88-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1129683-88-0 Usage

Uses

Used in Cardiovascular Medicine:
Ticagrelor is used as an antiplatelet agent for the prevention of blood clots in patients with acute coronary syndrome or a history of heart attack. It inhibits the P2Y12 receptor on platelets, reducing their ability to clump together and form clots, thus lowering the risk of cardiovascular events such as heart attack and stroke.
Used in Combination Therapy:
Ticagrelor is often used in combination with aspirin, a nonsteroidal anti-inflammatory drug, to provide a dual antiplatelet effect. This combination therapy enhances the prevention of blood clot formation and reduces the risk of cardiovascular events in patients with the aforementioned conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 1129683-88-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,2,9,6,8 and 3 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1129683-88:
(9*1)+(8*1)+(7*2)+(6*9)+(5*6)+(4*8)+(3*3)+(2*8)+(1*8)=180
180 % 10 = 0
So 1129683-88-0 is a valid CAS Registry Number.

1129683-88-0Downstream Products

1129683-88-0Relevant academic research and scientific papers

Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process

-

Page/Page column 22, (2010/12/29)

There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A) wherein R′ is selected from the group consisting of hydrogen, —C(O)OA, —C(O)CX3, —C(O)NH2, —C(O)—NHOH or There is also provided intermediate compounds of general formula (A), N-methyl-4-(4-ureidophenoxy)picolinamide, 4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenylcarbamate derivative and N-methyl-4-(4-(2,2,2-trihaloacetamido)phenoxy)picolinamide, processes for their preparation and their use in the preparation of sorafenib.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1129683-88-0